alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 12-7059

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

TITO DWAYNE TITUS,

Defendant - Appellant.

Appeal from the United States District Court for the District of 

South Carolina, at Columbia. Cameron McGowan Currie, District 

Judge. (3:10-cr-00585-CMC-1; 3:11-cv-02307-CMC)

Submitted: August 22, 2012 Decided: August 27, 2012

Before WILKINSON, GREGORY, and DIAZ, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Tito Dwayne Titus, Appellant Pro Se. Julius Ness Richardson, 

Assistant United States Attorney, Columbia, South Carolina, for 

Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Tito Dwayne Titus seeks to appeal the district court’s 

order denying relief on his 28 U.S.C.A. § 2255 (West Supp. 2012) 

motion. The order is not appealable unless a circuit justice or 

judge issues a certificate of appealability. 28 U.S.C. 

§ 2253(c)(1)(B) (2006). A certificate of appealability will not 

issue absent “a substantial showing of the denial of a 

constitutional right.” 28 U.S.C. § 2253(c)(2) (2006). When the 

district court denies relief on the merits, a prisoner satisfies 

this standard by demonstrating that reasonable jurists would 

find that the district court’s assessment of the constitutional 

claims is debatable or wrong. Slack v. McDaniel, 529 U.S. 473, 

484 (2000); see Miller-El v. Cockrell, 537 U.S. 322, 336-38 

(2003). When the district court denies relief on procedural 

grounds, the prisoner must demonstrate both that the dispositive 

procedural ruling is debatable, and that the motion states a 

debatable claim of the denial of a constitutional right. Slack, 

529 U.S. at 484-85. 

We have independently reviewed the record and conclude 

that Titus has not made the requisite showing. Accordingly, we 

deny a certificate of appealability and dismiss the appeal. We 

dispense with oral argument because the facts and legal
3

contentions are adequately presented in the materials before the 

court and argument would not aid the decisional process.

DISMISSED
OO

OOCH

3
[Federal Register Volume 75, Number 41 (Wednesday, March 3, 2010)]
[Notices]
[Page 9613]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4399]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated November 23, 2009, and published in the Federal 
Register on December 2, 2009 (74 FR 63156), ISP Freetown Fine 
Chemicals, 238 South Main Street, Assonet, Massachusetts 02702, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of Phenylacetone (8501), a basic class of 
controlled substance listed in schedule II.
    The company plans to import the controlled substance to manufacture 
amphetamine.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the 
registration of ISP Freetown Fine Chemicals to import the basic class 
of controlled substance is consistent with the public interest, and 
with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971, at this time. DEA 
has investigated ISP Freetown Fine Chemicals to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic class of controlled substance 
listed.

    Dated: February 25, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-4399 Filed 3-2-10; 8:45 am]
BILLING CODE 4410-09-P
UNPUBLISHED

UNITED STATES COURT OF APPEALS 

FOR THE FOURTH CIRCUIT 

No. 08-7286

UNITED STATES OF AMERICA, 

 Plaintiff - Appellee, 

 v. 

EDWIN FLORES, 

 Defendant - Appellant. 

Appeal from the United States District Court for the Eastern 

District of Virginia, at Alexandria. James C. Cacheris, Senior 

District Judge. (1:06-cr-00292-JCC-5)

Submitted: January 15, 2009 Decided: January 22, 2009 

Before MOTZ and SHEDD, Circuit Judges, and HAMILTON, Senior 

Circuit Judge. 

Affirmed by unpublished per curiam opinion. 

Edwin Flores, Appellant Pro Se. Jonathan Leo Fahey, Assistant 

United States Attorney, Alexandria, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit. 
2 

PER CURIAM: 

Edwin Flores appeals the district court’s order 

denying his motion for reduction of sentence, 18 U.S.C. 

§ 3582(c) (2006). We have reviewed the record and find no 

reversible error. Accordingly, we affirm for the reasons stated 

by the district court. United States v. Flores, No. 1:06-cr00292-JCC-5 (E.D. Va. July 2, 2008). We dispense with oral 

argument because the facts and legal contentions are adequately 

presented in the materials before the court and argument would 

not aid the decisional process. 

AFFIRMED
EXHIBIT 10.5


                                 PROMISSORY NOTE

$10,000.00                        Dallas, Texas                  August 14, 1998

         FOR VALUE  RECEIVED,  Preferred  Voice,  Inc.,  a Delaware  corporation
promises to pay to the order of Capital Growth Fund Ltd., at P.O. Box 3444, Road
Town,  Tortola,  British Virgin Islands,  or at such other address as the holder
hereof may designate,  the principal sum of Ten Thousand  Dollars  ($10,000.00),
together  with  interest on the unpaid  principal  balance  from the date hereof
until this note is paid in full at a rate of 10% per annum.

         Principal and interest  shall be payable in one  installment  on August
14, 1999.

         All payments  received shall be applied first to the payment of accrued
interest and then to the payment of principal.

         Maker shall have the right to prepay any and all amounts due  hereunder
without penalty for the privilege of doing so.

         No payment shall be considered in default  unless it is not paid within
ten (10) days after delivery of written notice of nonpayment.

         Holder will have the right at any time to convert this note into shares
of common stock,  $.001 par value per share, of Maker, at the conversion rate of
one share of common  stock for each $.50 of  principal  and  interest due on the
note on the date of conversion.

         In the event  default is made in the  payment of this Note,  the unpaid
balance on this Note shall at once become due and payable,  without  notice,  at
the option of the Holder. Failure to exercise this option shall not constitute a
waiver of the right to declare the entire  principal  due and payable at once at
any subsequent time.

         If, after default,  this Note is placed in the hands of an attorney for
collection,  or if collected  through judicial  proceeding,  Maker shall pay, in
addition to the sums  referred to above,  a reasonable  sum as a  collection  or
attorneys'  fee and all other  costs  incurred  by Holder in  collection  of the
unpaid amounts due hereunder.

         Each maker, surety,  guarantor,  endorser or other party liable for the
payment of this Note, in whole or in part,  hereby expressly waives  presentment
and demand for payment,  notice of intention to accelerate  maturity,  notice of
acceleration of maturity, protest and notice of protest and nonpayment, bringing
of suit and  diligence  in taking any action to collect sums owing  hereon,  and
agree that this Note,  and any payment  hereunder,  may be extended from time to
time without in any way affecting such liability.

MAKER:

Preferred Voice, Inc


----------------------
G. Ray Miller
Its: President
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1355 Helium. ( a ) Helium (empirical formula He, CAS Reg. No. 7440-59-7) is a colorless, odorless, flavorless, nonflammable, inert gas. It is lighter than air and is produced by the liquefaction and purification of natural gas.
( b ) The ingredient must be of a purity suitable for its intended use.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitations other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a processing aid as defined in § 170.3(o)(24) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 57270, Dec. 29, 1983, as amended at 73 FR 8607, Feb. 14, 2008]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7607 Reported in Senate (RS)]

<DOC>

                                                       Calendar No. 543
118th CONGRESS
  2d Session
                                H. R. 7607

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              June 4, 2024

Received; read twice and referred to the Committee on Homeland Security 
                        and Governmental Affairs

                           September 25, 2024

               Reported by Mr. Peters, without amendment

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at Block 1025, Lots 18 & 19, Northeast Corner of US Route 9 South and 
Main Street in the Township of Middle, County of Cape May, New Jersey, 
          as the ``George Henry White Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. GEORGE HENRY WHITE POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at Block 1025, Lots 18 & 19, Northeast Corner of US Route 9 
South and Main Street in the Township of Middle, County of Cape May, 
New Jersey, shall be known and designated as the ``George Henry White 
Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``George 
Henry White Post Office Building''.
                                                       Calendar No. 543

118th CONGRESS

  2d Session

                               H. R. 7607

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
 at Block 1025, Lots 18 & 19, Northeast Corner of US Route 9 South and 
Main Street in the Township of Middle, County of Cape May, New Jersey, 
          as the ``George Henry White Post Office Building''.

_______________________________________________________________________

                           September 25, 2024

                       Reported without amendment
```
§ 573.620 Menadione dimethylpyrimidinol bisulfite. The food additive, menadione dimethylpyrimidinol bisulfite, may be safely used in accordance with the following conditions: ( a ) The additive is the 2-hydroxy-4,6-dimethylpyrimidinol salt of menadione (C1 7H1 8O6N2S).
( b ) The additive is used or intended for use as a nutritional supplement for the prevention of vitamin K deficiency as follows: ( 1 ) In chicken and turkey feed at a level not to exceed 2 grams per ton of complete feed.
( 2 ) In the feed of growing and finishing swine at a level not to exceed 10 grams per ton of feed.
( c ) To assure safe use, the label and labeling of the additive shall bear adequate directions for use.
#### § 558.305 Laidlomycin.

(a) *Specifications.* Type A medicated articles containing 50 grams laidlomycin propionate potassium per pound.

(b) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.

(c) *Tolerances.* See § 556.346 of this chapter.

(d) *Special considerations.*

(1) Laidlomycin liquid Type B feeds may be manufactured from dry laidlomycin Type A articles. The liquid Type B feeds must have a pH of 6.0 to 8.0, dry matter of 62 to 75 percent, and bear appropriate mixing directions as follows:

(i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

(ii) For liquid feeds stored in mechanical, air, or other agitation type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) The expiration date for the liquid Type B feed is 21 days after date of manufacture. The expiration date for the dry Type C feed made from the liquid Type B feed is 7 days after date of manufacture.

(3) Labeling for all Type B feeds (liquid and dry) and Type C feeds containing laidlomycin shall bear the following statements:

(i) Do not allow horses or other equines access to feeds containing laidlomycin propionate potassium.

(ii) The safety of laidlomycin propionate potassium in unapproved species has not been established.

(iii) Not for use in animals intended for breeding.

(e) *Conditions of use.* It is used in cattle being fed in confinement for slaughter as follows:

| Laidlomycin in grams per ton | Combination in grams per ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (1) 5 | | For improved feed efficiency and increased rate of weight gain. | Feed continuously in a Type C feed at a rate of 30 to 75 mg/head/day. | 054771 |
| (2) 5 to 10 | | For improved feed efficiency. | Feed continuously in a Type C feed at a rate of 30 to 150 milligrams/head/day. | 054771 |

(f) Laidlomycin may also be used in combination with chlortetracycline as in § 558.128.

[59 FR 18297, Apr. 18, 1994, as amended at 60 FR 53509, Oct. 16, 1995; 62 FR 9929, Mar. 5, 1997; 63 FR 27845, May 21, 1998; 66 FR 46706, Sept. 7, 2001; 68 FR 13839, Mar. 21, 2003; 68 FR 42590, July 18, 2003; 69 FR 30198, May 27, 2004; 79 FR 13545, Mar. 11, 2014; 81 FR 95005, Dec. 27, 2016; 86 FR 14823, Mar. 19, 2021]
§ 640.16 Processing. ( a ) *Separation.* Within the timeframe specified in the directions for use for the blood collecting, processing, and storage system used, Red Blood Cells may be prepared either by centrifugation, done in a manner that will not tend to increase the temperature of the blood, or by normal undisturbed sedimentation. A portion of the plasma sufficient to insure optimal cell preservation shall be left with the red cells except when a cryoprotective substance or additive solution is added for prolonged storage.
( b ) *Sterile system.* All surfaces that come in contact with the red cells shall be sterile and pyrogen-free.
( c ) *Final containers.* Final containers used for Red Blood Cells shall be the original blood containers unless the method of processing requires a different container. The final container shall meet the requirements for blood containers prescribed in § 640.2(c). At the time of filing, if a different container is used, it shall be marked or identified by number or other symbol so as to relate it to the donor of that unit of red cells.
[38 FR 32089, Nov. 20, 1973, as amended at 43 FR 34460, Aug. 4, 1978; 50 FR 4139, Jan. 29, 1985; 64 FR 45372, Aug. 19, 1999; 66 FR 1836, Jan. 10, 2001; 66 FR 40890, Aug. 6, 2001]
§ 582.1275 Dextrans. ( a ) *Product.* Dextrans of average molecular weight below 100,000.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 530.10 Provision permitting extralabel use of animal drugs. An approved new animal drug or human drug intended to be used for an extralabel purpose in an animal is not unsafe under section 512 of the act and is exempt from the labeling requirements of section 502(f) of the act if such use is: ( a ) By or on the lawful written or oral order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship; and
( b ) In compliance with this part.
###### Editorial Note on Part 316

#### Editorial Note:

Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

#### § 316.2 Purpose.

The purpose of this part is to establish standards and procedures for determining eligibility for the benefits provided for in section 2 of the Orphan Drug Act, including written recommendations for investigations of orphan drugs, a 7-year period of exclusive marketing, and treatment use of investigational orphan drugs. This part is also intended to satisfy Congress' requirements that FDA promulgate procedures for the implementation of sections 525(a) and 526(a) of the act.
§ 610.15 Constituent materials. ( a ) *Ingredients, preservatives, diluents, adjuvants.* All ingredients used in a licensed product, and any diluent provided as an aid in the administration of the product, shall meet generally accepted standards of purity and quality. Any preservative used shall be sufficiently nontoxic so that the amount present in the recommended dose of the product will not be toxic to the recipient, and in the combination used it shall not denature the specific substances in the product to result in a decrease below the minimum acceptable potency within the dating period when stored at the recommended temperature. Products in multiple-dose containers shall contain a preservative, except that a preservative need not be added to Yellow Fever Vaccine; Poliovirus Vaccine Live Oral; viral vaccines labeled for use with the jet injector; dried vaccines when the accompanying diluent contains a preservative; or to an Allergenic Product in 50 percent or more volume in volume (v/v) glycerin. An adjuvant shall not be introduced into a product unless there is satisfactory evidence that it does not affect adversely the safety or potency of the product. The amount of aluminum in the recommended individual dose of a biological product shall not exceed: ( 1 ) 0.85 milligrams if determined by assay;
( 2 ) 1.14 milligrams if determined by calculation on the basis of the amount of aluminum compound added; or
( 3 ) 1.25 milligrams determined by assay provided that data demonstrating that the amount of aluminum used is safe and necessary to produce the intended effect are submitted to and approved by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research (see mailing addresses in § 600.2(a) or (b) of this chapter).
( b ) *Extraneous protein; cell culture produced vaccines.* Extraneous protein known to be capable of producing allergenic effects in human subjects shall not be added to a final virus medium of cell culture produced vaccines intended for injection. If serum is used at any stage, its calculated concentration in the final medium shall not exceed 1:1,000,000.
( c ) *Antibiotics.* A minimum concentration of antibiotics, other than penicillin, may be added to the production substrate of viral vaccines.
( d ) The Director of the Center for Biologics Evaluation and Research or the Director of the Center for Drug Evaluation and Research may approve an exception or alternative to any requirement in this section. Requests for such exceptions or alternatives must be in writing.
[38 FR 32056, Nov. 20, 1973, as amended at 46 FR 51903, Oct. 23, 1981; 48 FR 13025, Mar. 29, 1983; 48 FR 37023, Aug. 16, 1983; 49 FR 23834, June 8, 1984; 50 FR 4134, Jan. 29, 1985; 51 FR 15607, Apr. 25, 1986; 55 FR 11013, Mar. 26, 1990; 70 FR 14985, Mar. 24, 2005; 76 FR 20518, Apr. 13, 2011; 80 FR 18093, Apr. 3, 2015]
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 19
- 7654

UNITED STATES OF AMERICA , Plaintiff

- Appellee ,

v. BOBBY LEON JOHNSON , Defendant

- Appellant

.

Appeal from the United States District Court for the Western District of North Carolina , at Charlotte

. Martin K. Reidinger , District Judge. ( 3:01

- cr - 00210

- MR

- 1 ; 3:16

- cv - 00275

- MR )

Submitted : March 10, 2020 Decided: March 13, 2020

Before NIEMEYER and AGEE , Circuit Judges , and SHEDD, Senior Circuit Judge

.

Dismissed by un published per curiam opinion

. Bobby Leon Johnson , Appellant Pro Se.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Bobby Leon Johnson seeks to appeal the district court’s order granting the
Government’s motion to dismiss his 28 U.S.C. § 2255 (201 8 ) motion. The order is not appealable unless a circuit justice or judge issues a certificate of appealability. See
28 U.S.C. § 2253(c)(1)(B) (201 8 ). A certificate of appealability will not issue absent “a subs tantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (201 8 ). When the district court denies relief on the merits, a prisoner satisfies this standard by demonstrating that reasonable jurists would find the district court’s asse ssment of the constitutional claims debatable or wrong. See Buck v. Davis , 137 S. Ct. 759, 773

- 74 (2017). When the district court denies relief on procedural grounds, the prisoner must demonstrate both that the dispositive procedural ruling is debatable and that the motion states a debatable claim of the denial of a constitutional right. Gonzalez v. Thaler , 565 U.S. 134,
140

- 41 (2012) (citing Slack v. McDaniel , 529 U.S. 473, 484 (2000)). We have independently reviewed the record and conclude that Johns on has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this court and argu ment would not aid the decisional process.
DISMISSED
**EXHIBIT 23.1**

 

CONSENT OF INDEPENDENT PETROLEUM ENGINEERS AND GEOLOGISTS

 

 

We hereby consent to the use of the name Netherland, Sewell & Associates, Inc., to references to Netherland, Sewell & Associates, Inc. as independent petroleum engineers, and to the inclusion of information contained in our report as of December 31, 2007, in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, of Crimson Exploration Inc and in the registration statements (File No. 333-122987 and 333-151902) on Form S-8. 

 

**NETHERLAND, SEWELL & ASSOCIATES, INC.**

 

                

|   | By:    | /s/ Danny D. Simmons                  |
|--------|--------|---------------------------------------|
|   |   | Danny D. Simmons, P.E.                |
|   |   | President and Chief Operating Officer |

 

 

Houston, Texas

August 12, 2008